	Correction: LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway. Clin Exp Med Li Y, Zhao B, Gao W, Wu Y, Tian T, Zhao S, Zhang J, Li R, He S, Gong Y, Ma J, Li X. PMID: 41483418 [PubMed - in process]
	Exploring the use of preoperative MRI for assessing the anatomical location of positive surgical margin at robot-assisted radical prostatectomy (RARP). World J Urol van der Graaf SH, Boellaard TN, Vis AN, Sweere V, Veerman H, Wit EMK, Roeleveld TA, Nieuwenhuijzen JA, van der Poel HG, van Leeuwen PJ. PMID: 41483404 [PubMed - indexed for MEDLINE]
	Influence of diabetes mellitus and anti-diabetic drugs on pathophysiology and prognosis for primary prostate cancer. Int Urol Nephrol Kazachok M, , Zapa, Piecha T, Radziszewski P, Zapa. PMID: 41483135 [PubMed - as supplied by publisher]
	Sleep Duration and Prostate Cancer Risk in the Southern Community Cohort Study. Cancer Med Anukam DC, Nianogo RA, Arah OA, Boutros PC, Rao J, Fowke JH, Zhang ZF. PMID: 41482760 [PubMed - indexed for MEDLINE]
	Comparative Analysis of Immune-based Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma. In Vivo Mukae Y, Ohba K, Nakanishi H, Oki M, Kawada K, Matsuda T, Mitsunari K, Matsuo T, Mochizuki Y, Imamura R. PMID: 41482401 [PubMed - indexed for MEDLINE]
	Serum Zinc Levels and Skin-related Adverse Events During Systemic Therapy for Renal Cell Carcinoma. In Vivo Saito S, Sazuka T, Sato H, Watanabe Y, Yokochi F, Toma K, Onoda Y, Nagaoka K, Pae S, Sato K, Ando K, Yamada Y, Imamura Y, Sakamoto S. PMID: 41482397 [PubMed - indexed for MEDLINE]
	Identification of serum protein biomarkers for clear cell renal cell carcinoma using patient-derived xenografts. J Clin Invest Zhang D, Chiu CL, Garcia Marques FJ, Bermudez A, Hoerner CR, Hadi N, Wang E, Metzner TJ, Trabanino L, Leppert JT, Zhao H, Tibshirani R, Fan AC, Pitteri SJ, Brooks JD. PMID: 41480764 [PubMed - indexed for MEDLINE]
	Prognostic Significance of High-Risk versus Very High-Risk Classification in Non-Surgically Managed Prostate Cancer: A Retrospective Cohort Study. Cancer Manag Res A, Demir MS. PMID: 41480518 [PubMed]
	Advances in prostate cancer treatment with moderate and ultra-hypofractionated radiotherapy. World J Clin Oncol Meng LL, Di YP, Ma L, Qu BL. PMID: 41480171 [PubMed]
	Microfluidics and molecular diagnostics in renal cell carcinoma: advances, challenges, and future directions. Front Oncol Abu-Dawas SB, Alwadi AY, Farahat YH, Abu-Dawas RB, Quraiba LN, Abu-Omar RA, AlKattan K, Khan MI, Yaqinuddin A. PMID: 41479787 [PubMed]
	Deep learning-based dose prediction for prostate cancer with empty bladder protocol: a framework for efficient and personalized radiotherapy planning. Front Oncol Choi B, Shrestha DK, Attia A, Stish BJ, Leenstra J, Rwigema JC, Ma J, Lee SU, Jeong JH, Kim J, Kim J, Beltran C, Park JC. PMID: 41479786 [PubMed]
	Preoperative loco-regional assessment of prostate carcinoma using multi-parametric MRI and prostate-specific membrane antigen PET-computed tomography: correlation with histopathology. Nucl Med Commun Lal H, Malik D, Singh A, Prasad R, Sureka S, Nazar AH, Agarwal V, Kishun J, Yadav P, Jowel P. PMID: 41479341 [PubMed - as supplied by publisher]
	Comparison of Results from the BARCODE1 Study and Contemporary Prostate Cancer Screening Trials. Eur Urol Oncol Sud A, McNeill A, Vickers AJ. PMID: 41478782 [PubMed - as supplied by publisher]
	Perioperative and Oncological Outcomes of Distal Ureterectomy for Upper Tract Urothelial Carcinoma (UTUC): A Multicentre Study from the European Association of Urology Non-muscle-invasive Bladder Cancer/UTUC Guidelines Panels with a Focus on Survival Free from Ipsilateral UTUC Recurrence. Eur Urol Oncol Soria F, Liedberg F, Stahl E, Dominguez-Escrig JL, Moschini M, Pradere B, D'Andrea D, Teoh JY, Capoun O, Soukup V, Rai BP, Birtle A, Compérat EM, Mariappan P, van Rhijn BWG, Baard J, Seisen T, Xylinas EN, Shariat SF, Gontero P, Masson-Lecomte A. PMID: 41478781 [PubMed - as supplied by publisher]
	Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-GuÃ©rin (BCG) in BCG-naÃ¯ve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials. Eur Urol Scilipoti P, Zaurito P, Longoni M, Colecchia M, Montorsi F, Salonia A, Mercinelli C, Maiorano B, Necchi A, Briganti A, Moschini M. PMID: 41478774 [PubMed - as supplied by publisher]
	Multiplexed 3D-rGO/AuNP electrochemical aptasensor for ultrasensitive detection of urinary PSMA in prostate cancer diagnosis. Talanta Amin-Sadrabadi E, Koudehi MF, Behroozi J, Zibaseresht R, Chamanara M, Khomartash MS, Gorgani-Firuzjaee S, Fasihi Dastjerdi H, Heidari MF, Omidfar K. PMID: 41478044 [PubMed - as supplied by publisher]
	Incorporating physicians' contouring style into auto-segmentation of clinical target volume for post-operative prostate cancer radiotherapy using a language encoder. Mach Learn Health Zhao H, Liao CY, Yang D, Jiang S, Nguyen D. PMID: 41477361 [PubMed]
	The impact of diet and gut microbiota on development, treatment, and prognosis in prostate cancer. Front Nutr Liu G, Yang F, Song W, Hou R. PMID: 41477313 [PubMed]
	Identification and Validation of a Prognostic Signature Based on mRNAs Associated with Low-Density Lipoprotein Receptor-Related Proteins for Kidney Renal Clear Cell Carcinoma: Insights Into Tumor Immune Microenvironment, Mutation Patterns, and Personalized Treatment Strategies. Int J Gen Med Xie L, Zhou Y, Hu Z, Zhang S, Fan M, Huang X, Zhang W, Liu Z. PMID: 41477155 [PubMed]
	Machine learning-derived cellular senescence index for predicting prognosis and drug sensitivity in patients with renal cell carcinoma. Front Immunol Meng L, Zhang H, Qiu Y, Zhu X, Ji X, Wang B, Zhang G, Xue Y, Wang C. PMID: 41476960 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 174950

Page 1 of 8748



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy